journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis: Clinical and Laboratory Research

journal
https://www.readbyqxmd.com/read/28332941/functional-training-is-a-senseless-strategy-in-ms-cognitive-rehabilitation-strategy-training-is-the-only-useful-approach-commentary
#1
Bruno Brochet
No abstract text is available yet for this article.
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28332909/functional-training-is-a-senseless-strategy-in-ms-cognitive-rehabilitation-strategy-training-is-the-only-useful-approach-no
#2
Hanneke E Hulst, Dawn W Langdon
No abstract text is available yet for this article.
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28332907/functional-training-is-a-senseless-strategy-in-ms-cognitive-rehabilitation-strategy-training-is-the-only-useful-approach-yes
#3
Victoria M Leavitt
No abstract text is available yet for this article.
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28327056/multiple-sclerosis-and-suicide
#4
Anthony Feinstein, Bennis Pavisian
Mortality rates are elevated in people with multiple sclerosis (MS) relative to the general population. There is, however, some uncertainty whether suicide contributes to this. Epidemiological data suggest that the standardized mortality ratio (SMR) for suicide in MS is approximately twice that of the general population with younger males in the first few years following diagnosis most at risk. Rates of suicidal intent, a potential harbinger of more self-destructive behavior, are also elevated, but the frequency with which intent is followed by suicide is not known...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28326889/aquaporin-4-autoimmunity-in-patients-with-systemic-lupus-erythematosus-a-predominantly-population-based-study
#5
Nasrin Asgari, Sven Jarius, Helle Laustrup, Hanne Pb Skejoe, Soeren T Lillevang, Brian G Weinshenker, Anne Voss
BACKGROUND: Serum immunoglobulin G targeting the astrocyte water channel aquaporin-4 (AQP4) in the central nervous system (CNS) is a biomarker for neuromyelitis optica spectrum disease (NMOSD). Co-existence of NMOSD with systemic lupus erythematosus (SLE) putatively suggests susceptibility to antibody-mediated autoimmune disease. OBJECTIVE: To estimate the prevalence of NMOSD in SLE and investigate the immunogenetic background for an association of NMOSD and SLE...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28322606/cognitive-impairment-in-pediatric-onset-multiple-sclerosis-is-detected-by-the-brief-international-cognitive-assessment-for-multiple-sclerosis-and-computerized-cognitive-testing
#6
Leigh E Charvet, Michael Shaw, Ariana Frontario, Dawn Langdon, Lauren B Krupp
BACKGROUND: Cognitive impairment is a common and troubling feature of pediatric-onset multiple sclerosis (POMS). Brief cognitive assessment in the outpatient setting can identify and longitudinally monitor cognitive involvement so that early intervention is possible. OBJECTIVES: The goal of this study was to measure the sensitivity of two cognitive assessment approaches that are brief, repeatable, and suitable for clinical practice and for multicenter investigation...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28318370/patient-to-patient-transmission-of-natalizumab-associated-pml
#7
Reinhard Hohlfeld, Joachim Havla, Tania Kümpfel
No abstract text is available yet for this article.
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28304217/the-efficacy-of-teriflunomide-in-patients-who-received-prior-disease-modifying-treatments-subgroup-analyses-of-the-teriflunomide-phase-3-temso-and-tower-studies
#8
Mark S Freedman, Jerry S Wolinsky, Giancarlo Comi, Ludwig Kappos, Tomas P Olsson, Aaron E Miller, Karthinathan Thangavelu, Myriam Benamor, Philippe Truffinet, Paul W O'Connor
Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28301287/spinal-cord-lesions-a-modest-contributor-to-diagnosis-in-clinically-isolated-syndromes-but-a-relevant-prognostic-factor
#9
Georgina Arrambide, Alex Rovira, Jaume Sastre-Garriga, Carmen Tur, Joaquín Castilló, Jordi Río, Angela Vidal-Jordana, Ingrid Galán, Breogán Rodríguez-Acevedo, Luciana Midaglia, Carlos Nos, Patricia Mulero, Maria Jesús Arévalo, Manuel Comabella, Elena Huerga, Cristina Auger, Xavier Montalban, Mar Tintore
BACKGROUND: The usefulness of performing a spinal cord (SC) magnetic resonance imaging (MRI) in all clinically isolated syndromes (CIS) is controversial. OBJECTIVE: To assess the value of SC lesions for predicting multiple sclerosis (MS) diagnosis and disability accrual in CIS. METHODS: Concerning SC lesions and MS diagnosis (2010 McDonald), adjusted Cox regression analyses were performed in increasingly specific CIS groups: all cases ( n = 207), non-SC CIS ( n = 143), non-SC CIS with abnormal brain MRI ( n = 90) and non-SC CIS with abnormal brain MRI not fulfilling 2010 MS ( n = 67)...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28299962/what-is-the-risk-of-suicide-in-multiple-sclerosis
#10
Ruth Ann Marrie
No abstract text is available yet for this article.
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28299961/an-excessive-risk-of-suicide-may-no-longer-be-a-reality-for-multiple-sclerosis-patients
#11
Shoshannah Kalson-Ray, Gilles Edan, Emmanuelle Leray
BACKGROUND: Few recent studies have shown that there is no longer an increased risk of suicide in patients affected with multiple sclerosis (MS). OBJECTIVES: To describe suicide cases within a large French MS cohort and assess whether MS patients are at a higher risk of suicide compared with the general population. METHODS: Data derives from a study on long-term mortality of 27,603 prevalent cases from 15 MS specialist centres. Of 1,569 deceased MS patients (5...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28299951/closing-the-gap-on-employment-rates-success-stories-pave-the-way-for-policy-works-in-progress
#12
Lavanya Vijayasingham
No abstract text is available yet for this article.
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28294696/cerebrospinal-fluid-mtdna-concentration-is-elevated-in-multiple-sclerosis-disease-and-responds-to-treatment
#13
Cyra E Leurs, Petar Podlesniy, Ramon Trullas, Lisanne Balk, Martijn D Steenwijk, Arjan Malekzadeh, Fredrik Piehl, Bernard Mj Uitdehaag, Joep Killestein, Jack van Horssen, C E Teunissen
BACKGROUND: Mitochondrial dysfunction is increasingly recognized as an important feature of multiple sclerosis (MS) pathology and may be relevant for clinical disease progression. However, it is unknown whether mitochondrial DNA (mtDNA) levels in the cerebrospinal fluid (CSF) associate with disease progression and therapeutic response. OBJECTIVES: To evaluate whether CSF concentrations of mtDNA in MS patients can serve as a marker of ongoing neuropathology and may be helpful to differentiate between MS disease subtypes...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28294693/functional-network-connectivity-abnormalities-in-multiple-sclerosis-correlations-with-disability-and-cognitive-impairment
#14
Maria A Rocca, Paola Valsasina, Victoria M Leavitt, Mariaemma Rodegher, Marta Radaelli, Gianna C Riccitelli, Vittorio Martinelli, Filippo Martinelli-Boneschi, Andrea Falini, Giancarlo Comi, Massimo Filippi
OBJECTIVE: To investigate resting state (RS) functional connectivity (FC) abnormalities within the principal brain networks in a large cohort of multiple sclerosis (MS) patients, to define the trajectory of FC changes over disease stages and their relation with clinical and structural magnetic resonance imaging (MRI) measures. METHODS: RS functional magnetic resonance imaging (fMRI), clinical, and neuropsychological evaluation were obtained from 215 MS patients and 98 healthy controls...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28287331/disability-progression-markers-over-6-12%C3%A2-years-in-interferon-%C3%AE-treated-multiple-sclerosis-patients
#15
Jordi Río, Àlex Rovira, Mar Tintoré, Susana Otero-Romero, Manuel Comabella, Ángela Vidal-Jordana, Ingrid Galán, Joaquín Castilló, Georgina Arrambide, Carlos Nos, Carmen Tur, Berta Pujal, Cristina Auger, Jaume Sastre-Garriga, Xavier Montalban
OBJECTIVE: To investigate the association between activity during interferon-beta (IFNβ) therapy and disability outcomes in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: A longitudinal study based on two previously described cohorts of IFNβ-treated RRMS patients was conducted. Patients were classified according to clinical activity after 2 years (clinical cohort) or to clinical and radiological activity after 1 year (magnetic resonance imaging (MRI) cohort)...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28287051/body-size-and-physical-exercise-and-the-risk-of-multiple-sclerosis
#16
Marianna Cortese, Trond Riise, Kjetil Bjørnevik, Kjell-Morten Myhr
BACKGROUND: Whether large body size increases multiple sclerosis (MS) risk in men is not well understood. Concurrently, physical exercise could be an independent protective factor. OBJECTIVE: To prospectively investigate the association between body mass index (BMI) and aerobic fitness, indicators of body size and exercise, and MS risk in men. METHODS: We performed a population-based nested case-control study within the historical cohort of all Norwegian men, born in 1950-1975, undergoing mandatory conscription at the age of 19 years...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28287040/high-frequency-mri-monitoring-should-be-performed-in-natalizumab-treated-ms-patients-with-higher-risk-of-pml-commentary
#17
Mike P Wattjes, Clemens Warnke
No abstract text is available yet for this article.
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28287039/high-frequency-mri-monitoring-should-be-performed-in-natalizumab-treated-ms-patients-with-higher-risk-of-pml-yes
#18
Siew Mei Yap, Christopher McGuigan
No abstract text is available yet for this article.
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28287038/high-frequency-mri-monitoring-should-be-performed-in-natalizumab-treated-ms-patients-with-higher-risk-of-pml-no
#19
Christian Enzinger
No abstract text is available yet for this article.
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28287030/immediate-transient-thrombocytopenia-at-the-time-of-alemtuzumab-infusion-in-multiple-sclerosis
#20
Usha Ranganathan, Ulrike Kaunzner, Stacyann Foster, Timothy Vartanian, Jai S Perumal
BACKGROUND: Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). Although Immune thrombocytopenia (ITP) has been reported as a secondary autoimmune phenomenon following alemtuzumab infusion, immediate thrombocytopenia during the infusion has not been reported. OBJECTIVE: We report transient, reversible, self-limiting acute-onset thrombocytopenia during the first course with alemtuzumab. RESULTS AND CONCLUSION: In total, 3 of 22 paitents developed mild self-limited bruising associated with a drop in platelet count from their baseline during the intial 5-day course of alemtuzumab...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
journal
journal
32305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"